Biotech giant Amgen will appeal the decision of a European committee over its cancer treatment drug Vectibix. The European Committee for Medicinal Products for Human Use developed a negative view of the company’s marketing authorization application for Vectibix, used to treat patients with metastatic colorectal cancer who have failed chemotherapy. In accordance with European regulations, Amgen said it intends to request re-examination of the committee’s opinion by appealing. “Notwithstanding the CHMP’s initial view, Amgen is confident that the available data demonstrates that Vectibix improves progression-free survival for mCRC patients ” Amgen officials said in a written statement last week. Vectibix was approved by the FDA in September 2006.